Medipharma appoints Former President of Janssen Chris Halyk to its Board of Directors

pharmafile | August 4, 2020 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing  

Medipharma has appointed Chris Halyk, the former President of Janssen, to its Board of Directors. This is the third appointment made to the board this year.

Halyk has 35 years of experience in the pharmaceutical industry and 33 years with Johnson and Johnson. He has served in multiple roles in the company such as Vice-President, Sales and Marketing, a member of the Janssen Management Board, Managing Director of Ortho Biotech, the biopharmaceutical division of Janssen Inc and from 2006 until his retirement in 2019 as the President of Janssen Inc. 

Pat McCutcheon, Chief Executive Officer at MediPharm Labs, said on Halyk’s appointment: “Chris brings a wealth of pharmaceutical industry experience, deep leadership expertise and extensive connections to our Board earned while serving the largest and most diversified healthcare company in the world. His qualifications are very pertinent to MediPharm Labs as we advance our standing in the worldwide market for pharmaceutical-quality medical cannabis. We have set very high standards for membership on our Board and I am delighted that Chris has chosen to join us.”

In terms of education, Halyk has an Honours Business Administration degree from Ivey Business School at Western University. The company has granted 300,000 options to Halyk at an exercise prices and each grant has a five year term expiring on 31 July 2025.

Halyk said on his appointed that: “I am very impressed by MediPharm Labs evolution from start up to emerging medical cannabis industry leader and its commitment to GMP-grade pharmaceutical practices in all of its operations. I am also impressed with the evolution of its Board and leadership team. From my perspective, this is a company that is putting all the right pieces in place for long term, global success and I look forward to participating actively in its development.”

Conor Kavanagh

Related Content

No items found

Latest content